ライフサイエンスコーパス: severe aplastic anemia

1 l responses in some patients with refractory severe aplastic anemia.

2 mbopag in previously untreated patients with severe aplastic anemia.

3 ophosphamide is highly effective therapy for severe aplastic anemia.

4 produces durable treatment-free remission in severe aplastic anemia.

5 lin (ATG) plus cyclosporine in patients with severe aplastic anemia.

6 herapy in previously untreated patients with severe aplastic anemia.

7 ed toxicity was seen except one patient with severe aplastic anemia.

8 ar survival in patients who received HCT for severe aplastic anemia.

9 Severe aplastic anemia (AA) is a bone marrow (BM) failur

10 induces durable treatment-free remissions in severe aplastic anemia and a variety of other autoimmune

11 ion of the skin in an 11-year-old child with severe aplastic anemia and prolonged neutropenia is repo

12 whereas MECOM patients presented early-onset severe aplastic anemia, and ERCC6L2 patients, mild pancy

13 preferred for children and young adults with severe aplastic anemia, and immunosuppressive therapy is

14 d unrelated donor bone marrow transplant for severe aplastic anemia as a manifestation of Schwachman-

15 ferior to horse ATG as a first treatment for severe aplastic anemia, as indicated by hematologic resp

16 rbent assays in 18 consecutive patients with severe aplastic anemia before and after treatment with h

17 ons in telomere length have been reported in severe aplastic anemia but their clinical significance i

18 ge-adjusted telomere length of patients with severe aplastic anemia consecutively enrolled in immunos

19 one of the patients with the CFH variant had severe aplastic anemia from eculizumab initiation until

20 d 1993, 40 patients received transplants for severe aplastic anemia from related donors other than HL

21 o a distinct cell surface receptor and cause severe aplastic anemia in vivo and erythroblast destruct

22 Severe aplastic anemia is a life-threatening bone marrow

23 In a cohort of patients with severe aplastic anemia receiving immunosuppressive thera

24 nic immune thrombocytopenia, Evans syndrome, severe aplastic anemia/refractory cytopenia, and others.

25 About a quarter of patients with severe aplastic anemia remain pancytopenic despite immun

26 ministration for the treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 p

27 Severe aplastic anemia (SAA) appears to be an immunologi

28 Patients with severe aplastic anemia (SAA) are either treated with bon

29 Severe aplastic anemia (SAA) can be successfully treated

30 Patients with severe aplastic anemia (SAA) can have an unrecognized in

31 d donor bone marrow (BM) transplantation for severe aplastic anemia (SAA) has improved, with survival

32 Survival in severe aplastic anemia (SAA) has markedly improved in th

33 Severe aplastic anemia (SAA) is a life-threatening bone

34 Severe aplastic anemia (SAA) is a life-threatening bone

35 Severe aplastic anemia (SAA) is a marrow failure disorde

36 Severe aplastic anemia (SAA) is a rare disorder characte

37 Acquired severe aplastic anemia (SAA) is a rare hematologic disea

38 ble alternative donor becomes challenging in severe aplastic anemia (SAA) when a matched sibling dono

39 First-line therapy of severe aplastic anemia (SAA) with high-dose cyclophospha

40 In contrast to severe aplastic anemia (sAA), the appropriate management

41 e is effective in restoring hematopoiesis in severe aplastic anemia (SAA).

42 ed conditioning regimen in HSCT for acquired severe aplastic anemia (SAA).

43 geneic bone marrow transplantation (BMT) for severe aplastic anemia (SAA).

44 y) has been promoted as curative therapy for severe aplastic anemia (SAA).

45 results were noted in analyses stratified on severe aplastic anemia subtype, recipient age, HLA match

46 of hematologic response among patients with severe aplastic anemia than in a historical cohort.

47 in the great majority of young patients with severe aplastic anemia; the major challenges are extendi

48 dy, we analyzed results in 700 patients with severe aplastic anemia treated with allogeneic marrow tr

49 Approximately half of patients with severe aplastic anemia treated with antithymocyte globul

50 gkin Lymphoma, 1 Chronic Myeloid Leukemia, 2 Severe Aplastic Anemia) undergoing allo-HSCT.

51 Between 1970 and 1996, 333 patients with severe aplastic anemia underwent HLA-matched related mar

52 Bone marrow transplants for severe aplastic anemia were first performed in the 1970s

53 Severe aplastic anemia, which is characterized by immune

54 oach deserves further study in patients with severe aplastic anemia who are not suitable candidates f

55 le institution analysis of 183 patients with severe aplastic anemia who were treated in sequential pr

56 son Cancer Research Center for patients with severe aplastic anemia whose donors were HLA-nonidentica

57 nse among previously untreated patients with severe aplastic anemia, without additional toxic effects